Florea Anca-Maria, Neațu Monica, Luca Dimela-Gabriela, Davidescu Eugenia Irene, Popescu Bogdan-Ovidiu
Department of Clinical Neurosciences, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania.
Int J Mol Sci. 2025 May 7;26(9):4455. doi: 10.3390/ijms26094455.
The diagnostic algorithm for the demyelinating disorders of the central nervous system remains a work in progress, with the search for the ideal biomarkers ongoing. The so-called "ideal" biomarker should ensure the accurate differentiation between the most common demyelinating pathologies of the CNS and between the subtypes of the same pathology (for example, the conversion from relapsing-remitting multiple sclerosis to the secondary progressive phenotype). Advances in technology facilitated this research and in the following sections we will comprehensively review most of these, outlining the past, present, and prospects and the impact they had on both diagnosis and therapeutic approach.
中枢神经系统脱髓鞘疾病的诊断算法仍在不断完善中，寻找理想生物标志物的工作也在持续进行。所谓的“理想”生物标志物应能确保准确区分中枢神经系统最常见的脱髓鞘病变以及同一病变的不同亚型（例如，从复发缓解型多发性硬化症向继发进展型表型的转变）。技术进步推动了这项研究，在接下来的章节中，我们将全面回顾其中的大部分内容，概述其过去、现在和未来前景，以及它们对诊断和治疗方法的影响。
